Skip to content
Screener

Cogent Biosciences, Inc. COGT Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$624K-55.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M-33.3%
Immunome logo
ImmunomeIMNM
$446K-63.0%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$1.43M+260%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$445K-60.1%

Other financials

Income statement

See full
Operating income-$102.6M-35.8%
Net income-$96.4M-31.1%
EPS (diluted)-$0.52+1.9%

Balance sheet

See full
Cash & equivalents$181.2M+42.0%
Total debt$20.8M-65.7%
Total equity$532.4M+243%
Total assets$834.5M+204%

Cash flow

See full
Operating cash flow-$77.3M-41.7%
CapEx$370.0K+182%
Free cash flow-$77.6M-42.0%

Valuation

See full
Market cap$7.24B+374%
Enterprise value$7.08B+385%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-109.7%+2.3pp
Debt / equity-0.4×
Current ratio13.6×+9.4×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342393
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Depreciation and amortization expense1,3671,295
Stock-based compensation expense34,01519,724
Amortization of operating leases, right-of-use assets1,1571,000
Net amortization (accretion) of premiums (discounts) on marketable securities(2,141)(739)
Amortization of debt discount and issuance costs56263
Loss on fixed asset disposal134
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(1,538)2,235

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
Cogent Biosciences, Inc. (COGT) reported accretion (amortization) of discounts and premiums, investments of $961K in Q2 2026.
What does accretion (amortization) of discounts and premiums, investments mean?
Reflects the periodic adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value at maturity. This non-cash item reconciles the interest income recognized in the income statement with the actual cash yield of the investment portfolio. It is essential for understanding the true economic return on corporate cash holdings.

Ask your AI about Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude